Press "Enter" to skip to content

Cipla signs $22 mn pact with Pulmatrix Inc for new asthma drug

The agreement has been signed between the company’s wholly-owned subsidiary in the US, Cipla Technologies LLC with Pulmatrix Inc for an investment in phase 2 ready Pulmazole (inhaled ltraconazole).

Original source:

Also Read:   Coronavirus protein redesigned in lab, may enable fast, stable vaccine production: Study